**Name of Journal:** *World Journal of Cardiology*

**Manuscript NO:** 67222

**Manuscript Type:** MINIREVIEWS

**Predictors of persistence of functional mitral regurgitation after cardiac resynchronization therapy: review of literature**

Russo E *et al*. Functional mitral regurgitation in cardiac resynchronization therapy

Eleonora Russo, Giulio Russo, Maurizio Braccio, Mauro Cassese

**Eleonora Russo, Maurizio Braccio, Mauro Cassese,** Department of Cardiovascular Surgery, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo 71013, Italy

**Giulio Russo,** Institute of Cardiology, Catholic University of the Sacred Heart, Rome 00168, Italy

**Author contributions:** Russo E and Russo G contributed equally to this work and performed the conceptualization and writing of the original draft; Braccio M and Cassese M contributed to writing, reviewing and editing the manuscript.

**Corresponding author: Eleonora Russo, MD, PhD, Doctor,** Department of Cardiovascular Surgery, Casa Sollievo della Sofferenza Hospital, IRCCS, Viale Cappuccini 1, San Giovanni Rotondo 71013, Italy. elerusso81@hotmail.it

**Received:** April 18, 2021

**Revised:** October 10, 2021

**Accepted:** March 4, 2022

**Published online:** March 26, 2022

**Abstract**

Functional mitral regurgitation is a common finding among heart failure patients with ischemic and non-ischemic dilated cardiomyopathies. The presence of moderate or severe mitral regurgitation is associated with higher morbidity and mortality. Heart failure patients meeting electrocardiogram and left ventricle function criteria are good candidates for cardiac resynchronization therapy, which may reduce the degree of functional mitral regurgitation in the short and long term, specifically targeting myocardial dyssynchrony and inducing left ventricle reverse remodeling. In this article, we analyze data from the literature about predictors of mitral regurgitation improvement after cardiac resynchronization therapy implantation.

**Key Words:** Functional mitral regurgitation; Cardiac resynchronization therapy; Predictors; Mitral regurgitation improvement; Dyssynchrony

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Russo E, Russo G, Braccio M, Cassese M. Predictors of persistence of functional mitral regurgitation after cardiac resynchronization therapy: review of literature. *World J Cardiol* 2022; 14(3): 170-176

**URL:** <https://www.wjgnet.com/1949-8462/full/v14/i3/170.htm>

**DOI:** <https://dx.doi.org/10.4330/wjc.v14.i3.170>

**Core Tip:** Functional mitral regurgitation is a common finding among heart failure patients and, if moderate or severe, is associated with higher morbidity and mortality. Cardiac resynchronization therapy, as a therapy for a subset of heart failure patients, may determine a reduction of the degree of functional mitral regurgitation specifically targeting myocardial dyssynchrony and inducing left ventricle reverse remodeling. Here, we analyze predictors of mitral regurgitation improvement after cardiac resynchronization therapy implantation.

**INTRODUCTION**

Functional mitral regurgitation (FMR) is a common finding of left ventricular (LV) dysfunction and remodeling, occurring both in ischemic and non-ischemic heart disease[1]. The prevalence of FMR varies from 20% to 50% of heart failure (HF) patients[2,3], with 40% of patients presenting with moderate or severe mitral regurgitation (MR)[4]. Data from the literature suggest that any degree of FMR is associated with increased morbidity and reduced survival in patients with LV dysfunction[3-5]. In this setting, there is no conclusive evidence for a survival benefit after mitral valve intervention. The limited data regarding FMR result in a low level of evidence for treatment recommendations and highlight the importance of decision-making by the patient’s heart team. According to the latest guidelines, surgery is indicated in patients with severe secondary mitral regurgitation undergoing coronary artery bypass graft and LV ejection fraction > 30%[6,7]. When revascularization is not indicated, optimal medical therapy in line with the HF guidelines should be the first step. Furthermore, patients with HF and FMR eligible for cardiac resynchronization therapy (CRT) could benefit from resynchronization in terms of reduction of the degree of FMR[8,9]. Unlike medical therapy, CRT specifically targets myocardial dyssynchrony, which is an important factor of FMR onset. However, in a subset of CRT patients, significant MR persists and may even worsen.

The purpose of this paper is to provide a comprehensive review on predictors of improvement in FMR after CRT.

**ACUTE AND LONG-TERM EFFECTS OF CRT ON FMR IN THE PRESENCE OF DYSSYNCHRONY**

FMR results from multiple factors: ventricular remodeling, decreased contractility, impairment of mitral annular function, imbalance between tethering and closing forces, and mechanical dyssynchrony. LV mechanical dyssynchrony could be a potential contributing factor to FMR through several mechanisms. First, LV dilatation due to dyssynchrony leads to displacement of papillary muscles with consequent lack of leaflet coaptation. Second, uncoordinated regional mechanical activation due to dyssynchrony results in distorted mitral valve apparatus geometry[10]. Lastly, LV dyssynchrony generates a positive pressure gradient between the LV and the left atrium, leading to a diastolic FMR during incomplete mitral valve closure[11].

CRT effects may be distinguished as acute or chronic. Acute, short-term FMR reduction occurs suddenly after CRT implantation, while chronic, long-term FMR reduction occurs weeks to months after CRT implantation. Immediately after CRT device implantation, global LV contraction efficiency improves and closing forces increase consequently. Breithardt *et al*[12] first showed that an increase in LV dP/dt after CRT is directly correlated to MR reduction. Indeed an increase in LV dP/dt leads to an increase in transmitral pressure gradients that facilitate mitral valve leaflet coaptation. Furthermore, CRT acutely determines resynchronization of the papillary muscles leading to a shortening of MR duration and later onset of MR. Indeed, Kanzaki *et al*[13] showed that the inter-papillary muscleactivation time delay is the main determining factor related to MR in HF patients with left bundle branch block and that this delay is immediately improved by CRT.

Data from the literature suggest that short-term reduction in FMR after CRT implantation predicts a favorable clinical response, whereas FMR persistence is associated with reduced survival[14]. In addition to the early effect of CRT on FMR, long-term beneficial effects on FMR have been described. They are mainly represented by the increase of the closing forces and the global LV remodeling. Specifically, LV dimensions, shape and function are main determinants of FMR, and CRT attenuates LV remodeling, which therefore improves FMR. These results could be achieved after 3–6 mo of CRT on top of optimized medical treatment and are even more evident during longer follow-up[15].

Large randomized trials have confirmed short and long-term reduction of FMR following CRT implantation, although the magnitude of this reduction is modest (20%–35% using different quantification methods)[16,17]. In 20%–25% of CRT patients, significant MR persists and may even worsen in 10%-15%. Specifically, this concerns patients with grade ≥ 2 FMR who have a significantly worse outcome than other CRT patients. This subset of patients is often found to be CRT non-responders, and the reasons why these patients do not benefit from CRT are still unclear.

**PREDICTORS OF IMPROVEMENT OF FMR AFTER CRT IMPLANTATION**

Data from the literature show that reductions in MR occur mainly in patients with response to CRT. However, FMR reduction was also demonstrated in CRT non-responders. Porciani *et al*[18] reported that FMR may improve even in CRT non-responders because of the reversal of LV dyssynchrony. Reversal of LV mechanical dyssynchrony, especially at the papillary muscle level, has been suggested as one of the mechanisms implicated in CRT-induced FMR improvement[19]. Reviewing the literature, several predictors of MR improvement in CRT patients were found and can be distinguished by patient, clinical, imaging and electric-targeting LV lead-related predictors.

**PATIENT-RELATED PREDICTORS**

Karaca *et al*[20] analyzed142 patients who received biventricular pacemaker devices and found that ΔQRS (baseline - paced) after CRT [hazard ratio (HR): 1.242, 95% confidence interval (CI): 1.019-1.465, *P* = 0.028] was associated with LV reverse remodeling and reduced FMR at 6 mo. There were also lower rates of death or hospitalization at midterm follow-up. The cut-off ΔQRS value to predict FMR response after CRT was 20 mo, with a sensitivity of 72% and a specificity of 85%. Multivariate analysis found that ΔQRS was an independent predictor of FMR response at 6 mo. The same authors observed that non-ischemic HF etiology [odds ratio (OR): 3.13, 95%CI: 1.169-8.380, *P* = 0.021] and the baseline presence of left bundle branch block morphology (OR: 2.49, 95%CI: 1.086-5.714, *P* = 0.032) were independent predictors of “reverse mitral remodeling” and predictors of MR amelioration[21]. The abovementioned preoperative features are those that the majority of previous CRT studies found as “classical” predictors of CRT response.

Sadeghian *et al*[22], in a small study of 69 patients, found that independent predictors of early MR improvement (48 h after CRT implantation) were older age and longer baseline QRS duration. Among the MR improvement group, the mean age was 60 ± 7 years (*vs* 55 ± 12 years in the no MR improvement group), and baseline QRS width was 172 ± 31 ms (*vs* 147 ± 28 ms).

Profibrotic biomarkers were also evaluated as potential predictors of FMR reduction. It was found that at the time of CRT device implantation, elevated concentrations of gal-3, a protein (lectin family) upregulated in HF that is involved in fibrogenesis, are associated with a lack of MR amelioration (OR: 0.14, 95%CI: 0.03-0.58, *P* = 0.007)[23]. These result are consistent with molecular changes in HF settings where fibroblast proliferation and collagen production have a pivotal role on LV remodeling and consequently in mitral annulus dilatation/dysfunction.

**IMAGING-RELATED PREDICTORS**

Sitges *et al*[24] found that baseline mitral valve tenting area, as a remodeling parameter of the mitral valve, was a powerful independent predictor of MR reduction with CRT(OR: 8.05, 95%CI: 1.15-56.60, *P* = 0.03). A cut-off value > 3.8 cm2yielded sensitivity of 53% and specificity of 89% to predict the absence of a significant reduction in MR with CRT. Similar results have been reported for predicting the success of restrictive annuloplasty in patients with functional MR who undergo surgery. Indeed, Magne *et al*[25] reported that a tenting area > 2.5 cm2 was associated with failed mitral valve repair in these patients. Results described by Sitges *et al*[24] were confirmed subsequently by Karaca *et al*[21]. In that study, baseline tenting area was identified as an independent predictor of FMR response at 6 mo (HR: 2.011, 95%CI: 1.268-2.754, *P* = 0.012). Values of tenting area differed significantly in FMR responders compared with non-responders (4.68 ± 1.02 cm2 *vs* 3.22 ± 0.88 cm2, *P* = 0.002). These data suggest that the more advanced the LV remodeling and the more distorted the LV geometry, the lower the probability of effective treatment for functional MR.

Subsequently, studies were performed with tissue Doppler imaging (TDI) and speckle tracking echocardiography to elucidate the role of myocardial dyssynchrony in the genesis of FMR in HF patients. Sadeghian *et al*[22] showed that septolateral delay by TDI was a significant predictor of MR improvement. In a previous small study with moderate/severe MR patients, Karvounis *et al*[26] showed that inferior papillary muscle time delay (R2 = 0.945, *P* = 0.04) together with an increase in posterior papillary muscle longitudinal negative strain (R2 = 0.727, *P* = 0.01) (both evaluated with TDI) were significant predictors of reduction in MR volume post-CRT implantation.

Naqvi *et al*[27] found that septolateral delay of > 60 ms was a univariate but not a multivariate predictor of MR reduction and demonstrated that the combined presence of delayed longitudinal strain in the mid inferior LV segment along with preserved systolic strain in the basal and mid posterior segments predicted reduction in MR severity post-CRT. The sensitivity and specificity of this composite variable to predict follow-up MR was 88% and 93%, respectively. These aforementioned findings added important information about acute MR reduction post-CRT. Indeed, patients who developed significant MR reduction had discoordination at the mid ventricle level. Therefore, the mid anterolateral segments were the earliest, and the mid inferoposterior segments were the most delayed as well as viable segments. This suggested delayed posterior papillary muscle compared to anterior papillary muscle contraction resulted in malcoaptation of mitral leaflets and MR. Therefore, CRT in the MR improvement group probably reduced MR by correcting the mid inferoposterior wall delay and by improving function in these viable segments as assessed by strain and strain rate.

Unlike these studies, Goland *et al*[28] evaluated radial instead of longitudinal strain and used a two-dimensional method of strain assessment instead of TDI. It was found on multivariable logistic analysis that time to peak two-dimensional radial strain between inferior and anterior LV segments of > 110 ms (OR: 8.4, 95%CI: 8.4–54.0, *P* = 0.02) and two-dimensional radial strain in the posterior segment of > 18% were significant predictors of early post-CRT MR improvement (OR: 7.6, 95%CI: 1.2–72.4, *P* = 0.006). These results confirmed the role of viability and dyssynchrony of the areas adjacent to posterior papillary muscle. Obviously, the presence of non-severe MR predicted MR reduction after CRT as suggested by MR jet area/Left area ratio (OR: 8.1, 95%CI: 1.2–52.4, *P* = 0.02).

Onishi *et al*[29], in a large series, showed that anteroseptal to posterior wall radial strain dyssynchrony > 200 ms (OR: 2.65, 95%CI:1.11–6.30, *P* = 0.0277) and end systolic dimension index < 29 mm/m2 (OR: 2.53, 95%CI: 1.03–6.20, *P* = 0.0420) predicted MR improvement at 6 mo after CRT implantation. Therefore, the present study combined the presence of radial dyssynchrony and lack of excessive LV dilatation (simply measured by end-systolic diameter index) with strong amelioration of significant MR. Furthermore, it added another important element: the lack of echocardiographic scar at the papillary muscle insertion site (wall motion score index ≤ 2.5) that resulted as a significant predictor of MR improvement (OR: 2.59, 95%CI: 1.06–6.30, *P* = 0.0360).

An interesting study was recently conducted by Galand *et al*[30]. It included 54 HF patient candidates for CRT who underwent dual-source computed tomography (CT) scan imaging in order to guide the CRT implantation procedure. Cardiac dual-source computed tomography is an ideal non-invasive imaging modality with very fast features, so patients receive less radiation. It also creates sharper images. This study evaluated the impact of LV wall thickness using dual-source CT in response to CRT and MR improvement. In multivariable analysis, an area ≥ 25% of LV wall thickness < 6 mm including at least one papillary muscle insertion was the only predictor of no MR improvement at 6 mo (OR: 16.82, 95%CI: 1.72–164.2, *P* = 0.015). The study confirmed the crucial role of papillary muscle insertion site and suggested that normal wall thickness could promote a mitral valve apparatus remodeling after CRT.

**ELECTRIC-TARGETING LV LEAD-RELATED PREDICTORS**

Among invasive electric predictors of the response to CRT, a commonly studied measure of electric delay is the QLV interval, which is the time from the onset of the QRS complex on the surfaceelectrocardiogram to the local LV activation at the site of the LV lead[31]. Previous studies demonstrated the predictive value of QLV interval as a measure of LV electric delay for acute hemodynamic changes and clinical outcome with CRT[32]. Recently, Upadhyay *et al*[33] provided an interesting link between a simple electric measurement, such as QLV, and improvement in MR. They demonstrated that greater changes in MR were achieved by targeting the LV lead in regions of longer QLV at implant (multivariate β coefficient = 0.0040, *P* = 0.0072).

Chatterjee *et al*[34] analyzed data from patients enrolled in the SMART-AV study[29] and provided strong evidence of the association between baseline QLV and reduction in MR after CRT. After multivariable adjustment, increasing QLV was an independent predictor of MR reduction at 6 mo as reflected by an increased odds of MR response (OR: 1.13, 95%CI: 1.03–1.25/10 ms increase QLV, *P* = 0.02).

**STUDY LIMITATIONS**

This was not a systematic review. Heterogeneity among included studies was widespread. Studies included showed variations in study design, cohort characteristics and response definitions. Another source of heterogeneity is that CRT implantation techniques and indications have evolved over the last 20 years. These limitations are particularly important to consider in future research studies.

**CONCLUSION**

Over the past two decades, numerous invasive and non-invasive predictors of the response to CRT have been proposed, and it was shown that reductions in MR occurred mainly in patients with response to CRT (Table 1). However, not all CRT responders are “MR responders,” and FMR reduction was also demonstrated in CRT non-responders, hence the importance of identifying MR improvement predictors after CRT implantation. Among “MR predictors” proposed, the possibility to recognize viability and dyssynchrony by imaging, especially near papillary muscles, is very useful. Also the measurement of LV electric ventricular delay, such as QLV, is simple, does not require echocardiography or surface electrocardiographic measurements and has the potential to be measured automatically by devices that would further simplify lead optimization.

The concept that more advanced LV remodeling remains valid. Therefore, the lower the probability of successful CRT treatment for FMR and other treatment strategies to reduce MR should be evaluated. Long-term results in a larger cohort together with new imaging techniques, such as three-dimensional imaging, are needed to keep track of the developments and the changes in this exciting field.

**REFERENCES**

1 **Enriquez-Sarano M**, Akins CW, Vahanian A. Mitral regurgitation. *Lancet* 2009; **373**: 1382-1394 [PMID: 19356795 DOI: 10.1016/S0140-6736(09)60692-9]

2 **Rossi A**, Dini FL, Faggiano P, Agricola E, Cicoira M, Frattini S, Simioniuc A, Gullace M, Ghio S, Enriquez-Sarano M, Temporelli PL. Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. *Heart* 2011; **97**: 1675-1680 [PMID: 21807656 DOI: 10.1136/hrt.2011.225789]

3 **Grigioni F**, Enriquez-Sarano M, Zehr KJ, Bailey KR, Tajik AJ. Ischemic mitral regurgitation: long-term outcome and prognostic implications with quantitative Doppler assessment. *Circulation* 2001; **103**: 1759-1764 [PMID: 11282907 DOI: 10.1161/01.cir.103.13.1759]

4 **Buja P**, Tarantini G, Del Bianco F, Razzolini R, Bilato C, Ramondo A, Napodano M, Isabella G, Gerosa G, Iliceto S. Moderate-to-severe ischemic mitral regurgitation and multivessel coronary artery disease: Impact of different treatment on survival and rehospitalization. *Int J Cardiol* 2006; **111**: 26-33 [PMID: 16061295 DOI: 10.1016/j.ijcard.2005.06.035]

5 **Agricola E**, Stella S, Figini F, Piraino D, Oppizzi M, D'Amato R, Slavich M, Ancona MB, Margonato A. Non-ischemic dilated cardiopathy: prognostic value of functional mitral regurgitation. *Int J Cardiol* 2011; **146**: 426-428 [PMID: 21094544 DOI: 10.1016/j.ijcard.2010.10.096]

6 **Baumgartner H**, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2017; **38**: 2739-2791 [PMID: 28886619 DOI: 10.1093/eurheartj/ehx391]

7 **Writing Committee Members.**, Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM 3rd, Thompson A, Toly C. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol* 2021; **77**: 450-500 [PMID: 33342587 DOI: 10.1016/j.jacc.2020.11.035]

8 **Cazeau S**, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, Garrigue S, Kappenberger L, Haywood GA, Santini M, Bailleul C, Daubert JC; Multisite Stimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. *N Engl J Med* 2001; **344**: 873-880 [PMID: 11259720 DOI: 10.1056/NEJM200103223441202]

9 **Cleland JG**, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med* 2005; **352**: 1539-1549 [PMID: 15753115 DOI: 10.1056/NEJMoa050496]

10 **Nielsen SL**, Nygaard H, Mandrup L, Fontaine AA, Hasenkam JM, He S, Yoganathan AP. Mechanism of incomplete mitral leaflet coaptation--interaction of chordal restraint and changes in mitral leaflet coaptation geometry. Insight from in vitro validation of the premise of force equilibrium. *J Biomech Eng* 2002; **124**: 596-608 [PMID: 12405603 DOI: 10.1115/1.1500741]

11 **Ishikawa T**, Kimura K, Miyazaki N, Tochikubo O, Usui T, Kashiwagi M, Ishii M. Diastolic mitral regurgitation in patients with first-degree atrioventricular block. *Pacing Clin Electrophysiol* 1992; **15**: 1927-1931 [PMID: 1279574 DOI: 10.1111/j.1540-8159.1992.tb02996.x]

12 **Breithardt OA**, Sinha AM, Schwammenthal E, Bidaoui N, Markus KU, Franke A, Stellbrink C. Acute effects of cardiac resynchronization therapy on functional mitral regurgitation in advanced systolic heart failure. *J Am Coll Cardiol* 2003; **41**: 765-770 [PMID: 12628720 DOI: 10.1016/s0735-1097(02)02937-6]

13 **Kanzaki H**, Bazaz R, Schwartzman D, Dohi K, Sade LE, Gorcsan J 3rd. A mechanism for immediate reduction in mitral regurgitation after cardiac resynchronization therapy: insights from mechanical activation strain mapping. *J Am Coll Cardiol* 2004; **44**: 1619-1625 [PMID: 15489094 DOI: 10.1016/j.jacc.2004.07.036]

14 **van Bommel RJ**, Marsan NA, Delgado V, Borleffs CJ, van Rijnsoever EP, Schalij MJ, Bax JJ. Cardiac resynchronization therapy as a therapeutic option in patients with moderate-severe functional mitral regurgitation and high operative risk. *Circulation* 2011; **124**: 912-919 [PMID: 21810666 DOI: 10.1161/CIRCULATIONAHA.110.009803]

15 **Solis J**, McCarty D, Levine RA, Handschumacher MD, Fernandez-Friera L, Chen-Tournoux A, Mont L, Vidal B, Singh JP, Brugada J, Picard MH, Sitges M, Hung J. Mechanism of decrease in mitral regurgitation after cardiac resynchronization therapy: optimization of the force-balance relationship. *Circ Cardiovasc Imaging* 2009; **2**: 444-450 [PMID: 19920042 DOI: 10.1161/CIRCIMAGING.108.823732]

16 **Di Biase L**, Auricchio A, Mohanty P, Bai R, Kautzner J, Pieragnoli P, Regoli F, Sorgente A, Spinucci G, Ricciardi G, Michelucci A, Perrotta L, Faletra F, Mlcochová H, Sedlacek K, Canby R, Sanchez JE, Horton R, Burkhardt JD, Moccetti T, Padeletti L, Natale A. Impact of cardiac resynchronization therapy on the severity of mitral regurgitation. *Europace* 2011; **13**: 829-838 [PMID: 21486916 DOI: 10.1093/europace/eur047]

17 **Cipriani M**, Lunati M, Landolina M, Proclemer A, Boriani G, Ricci RP, Rordorf R, Matassini MV, Padeletti L, Iacopino S, Molon G, Perego GB, Gasparini M; Italian ClinicalService Project Investigators. Prognostic implications of mitral regurgitation in patients after cardiac resynchronization therapy. *Eur J Heart Fail* 2016; **18**: 1060-1068 [PMID: 27412374 DOI: 10.1002/ejhf.569]

18 **Porciani MC**, Macioce R, Demarchi G, Chiostri M, Musilli N, Cappelli F, Lilli A, Ricciardi G, Padeletti L. Effects of cardiac resynchronization therapy on the mechanisms underlying functional mitral regurgitation in congestive heart failure. *Eur J Echocardiogr* 2006; **7**: 31-39 [PMID: 16378918 DOI: 10.1016/j.euje.2005.03.008]

19 **Vinereanu D**. Mitral regurgitation and cardiac resynchronization therapy. *Echocardiography* 2008; **25**: 1155-1166 [PMID: 18986402 DOI: 10.1111/j.1540-8175.2008.00781.x]

20 **Karaca O**, Omaygenc MO, Cakal B, Cakal SD, Gunes HM, Barutcu I, Boztosun B, Kilicaslan F. Effect of QRS Narrowing After Cardiac Resynchronization Therapy on Functional Mitral Regurgitation in Patients With Systolic Heart Failure. *Am J Cardiol* 2016; **117**: 412-419 [PMID: 26721652 DOI: 10.1016/j.amjcard.2015.11.010]

21 **Karaca O**, Cakal B, Omaygenc MO, Gunes HM, Kizilirmak F, Cakal SD, Naki DD, Barutcu I, Boztosun B, Kilicaslan F. Effect of cardiac resynchronization therapy on mitral valve geometry: a novel aspect as "reversed mitral remodeling". *Int J Cardiovasc Imaging* 2018; **34**: 1029-1040 [PMID: 29387972 DOI: 10.1007/s10554-018-1308-2]

22 **Sadeghian H**, Lotfi-Tokaldany M, Montazeri M, Kazemi Saeed A, Sahebjam M, Sardari A, Ejmalian G. Early Improvement in Mitral Regurgitation after Cardiac Resynchronization Therapy in Cardiomyopathy Patients. *J Heart Valve Dis* 2017; **26**: 557-563 [PMID: 29762924]

23 **Beaudoin J**, Singh JP, Szymonifka J, Zhou Q, Levine RA, Januzzi JL, Truong QA. Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study. *Can J Cardiol* 2016; **32**: 1478-1484 [PMID: 27527259 DOI: 10.1016/j.cjca.2016.05.013]

24 **Sitges M**, Vidal B, Delgado V, Mont L, Garcia-Alvarez A, Tolosana JM, Castel A, Berruezo A, Azqueta M, Pare C, Brugada J. Long-term effect of cardiac resynchronization therapy on functional mitral valve regurgitation. *Am J Cardiol* 2009; **104**: 383-388 [PMID: 19616672 DOI: 10.1016/j.amjcard.2009.03.060]

25 **Magne J**, Pibarot P, Dagenais F, Hachicha Z, Dumesnil JG, Sénéchal M. Preoperative posterior leaflet angle accurately predicts outcome after restrictive mitral valve annuloplasty for ischemic mitral regurgitation. *Circulation* 2007; **115**: 782-791 [PMID: 17283262 DOI: 10.1161/CIRCULATIONAHA.106.649236]

26 **Karvounis HI**, Dalamaga EG, Papadopoulos CE, Karamitsos TD, Vassilikos V, Paraskevaidis S, Styliadis IH, Parharidis GE, Louridas GE. Improved papillary muscle function attenuates functional mitral regurgitation in patients with dilated cardiomyopathy after cardiac resynchronization therapy. *J Am Soc Echocardiogr* 2006; **19**: 1150-1157 [PMID: 16950470 DOI: 10.1016/j.echo.2006.04.022]

27 **Naqvi TZ**, Rafique AM, Swerdlow C, Verma S, Siegel RJ, Tolstrup K, Kerwin W, Goodman J, Gallik D, Gang E, Peter CT. Predictors of reduction in mitral regurgitation in patients undergoing cardiac resynchronisation treatment. *Heart* 2008; **94**: 1580-1588 [PMID: 18467354 DOI: 10.1136/hrt.2007.118356]

28 **Goland S**, Rafique AM, Mirocha J, Siegel RJ, Naqvi TZ. Reduction in mitral regurgitation in patients undergoing cardiac resynchronization treatment: assessment of predictors by two-dimensional radial strain echocardiography. *Echocardiography* 2009; **26**: 420-430 [PMID: 19382944 DOI: 10.1111/j.1540-8175.2008.00823.x]

29 **Onishi T**, Onishi T, Marek JJ, Ahmed M, Haberman SC, Oyenuga O, Adelstein E, Schwartzman D, Saba S, Gorcsan J 3rd. Mechanistic features associated with improvement in mitral regurgitation after cardiac resynchronization therapy and their relation to long-term patient outcome. *Circ Heart Fail* 2013; **6**: 685-693 [PMID: 23733917 DOI: 10.1161/CIRCHEARTFAILURE.112.000112]

30 **Galand V**, Ghoshhajra B, Szymonifka J, Das S, Orencole M, Barré V, Martins RP, Leclercq C, Hung J, Truong QA, Singh JP. Left ventricular wall thickness assessed by cardiac computed tomography and cardiac resynchronization therapy outcomes. *Europace* 2020; **22**: 401-411 [PMID: 31865389 DOI: 10.1093/europace/euz322]

31 **Singh JP**, Fan D, Heist EK, Alabiad CR, Taub C, Reddy V, Mansour M, Picard MH, Ruskin JN, Mela T. Left ventricular lead electrical delay predicts response to cardiac resynchronization therapy. *Heart Rhythm* 2006; **3**: 1285-1292 [PMID: 17074633 DOI: 10.1016/j.hrthm.2006.07.034]

32 **Gold MR**, Singh JP, Ellenbogen KA, Yu Y, Wold N, Meyer TE, Birgersdotter-Green U. Interventricular Electrical Delay Is Predictive of Response to Cardiac Resynchronization Therapy. *JACC Clin Electrophysiol* 2016; **2**: 438-447 [PMID: 29759863 DOI: 10.1016/j.jacep.2016.02.018]

33 **Upadhyay GA**, Chatterjee NA, Kandala J, Friedman DJ, Park MY, Tabtabai SR, Hung J, Singh JP. Assessing mitral regurgitation in the prediction of clinical outcome after cardiac resynchronization therapy. *Heart Rhythm* 2015; **12**: 1201-1208 [PMID: 25708879 DOI: 10.1016/j.hrthm.2015.02.022]

34 **Chatterjee NA**, Gold MR, Waggoner AD, Picard MH, Stein KM, Yu Y, Meyer TE, Wold N, Ellenbogen KA, Singh JP. Longer Left Ventricular Electric Delay Reduces Mitral Regurgitation After Cardiac Resynchronization Therapy: Mechanistic Insights From the SMART-AV Study (SmartDelay Determined AV Optimization: A Comparison to Other AV Delay Methods Used in Cardiac Resynchronization Therapy). *Circ Arrhythm Electrophysiol* 2016; **9** [PMID: 27906653 DOI: 10.1161/CIRCEP.116.004346]

**Footnotes**

**Conflict-of-interest statement:** All authors declare that there are no any conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model**: Single blind

**Peer-review started:** April 18, 2021

**First decision:** September 2, 2021

**Article in press:** March 4, 2022

**Specialty type:** Cardiac and cardiovascular systems

**Country/Territory of origin:** Italy

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Hong X, China; Sawalha K, United States **S-Editor:** Ma YJ **L-Editor:** A **P-Editor:** Ma YJ

**Table 1 variables that predict mitral regurgitation improvement or lack of improvement**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Predictor category** | **Predictors of MR improvement** | **Ref.** | **HR** | ***P* value** |
| Clinical parameters | ΔQRS (at least 20 ms) after CRT | [20] | 1.242 | 0.028 |
|  | Non ischemic HF etiology | [20] | 3.13 | 0.021 |
|  | Baseline presence of LBBB morphology | [20] | 2.49 | 0.032 |
|  | QRS narrowing after CRT | [21] | NA | 0.001 |
|  | Older age | [23] | NA | 0.001 |
|  | Baseline longer QRS duration | [23] | NA | 0.001 |
| Echo imaging | Septal-lateral delay by TDI | [23] | NA | 0.001 |
|  | Baseline tenting area < 3.8 cm2 | [24] | NA | 0.02 |
|  | Baseline tenting area | [21] | NA | 0.01 |
|  | Septal-lateral delay by TDI | [22] | NA | 0.001 |
|  | Baseline inferior papillary muscle time delay | [26] | NA | 0.04 |
|  | Increase in posterior papillary muscle longitudinal negative strain | [26] | NA | 0.01 |
|  | Combined presence of delayed longitudinal strain in the mid inferior LV segment and preserved systolic strain in the basal and mid posterior segments | [27] | NA | 0.001 |
|  | Time to- peak 2-DRS between inferior and anterior LV segments of > 110 ms | [28] | 8.4 | 0.02 |
|  | Preserved radial strain in posterior segments assessed by 2-DRS | [28] | 7.6 | 0.006 |
|  | MR jet area/left atrium area ratio < 40% | [28] | 8.9 | 0.02 |
|  | Anteroseptal to posterior wall radial strain dyssynchrony > 200 ms | [29] | NA | 0.028 |
|  | Lack of severe left ventricular dilatation (end-systolic dimension index < 29 mm/m2) | [29] | NA | 0.042 |
|  | Lack of echocardiographic scar at papillary muscle insertion sites | [29] | NA | 0.036 |
| Electric-Targeting LV Lead | Degree of delay at the LV lead site | [34] | 1.13 | 0.02 |
|  | Predictors of lack of MR improvement |  |  |  |
| CT imaging | ≥ 25% of LVWT < 6 mm inclusive of at least one papillary muscle insertion using CT | [30] | 1.04 | 0.032 |
| Biomarkers | Higher levels of galectin 3 | [23] | 0.16 | 0.01 |

CRT: Cardiac resyncronization therapy; TDI: Tissue Doppler imaging; 2DRS: 2D radial strain; MR: Mitral regurgitation; LVWT: Left ventricular wall thickness; CT: Computed tomography; LV: Left ventricular; NA: Not available.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**